Literature DB >> 22029828

Fractional exhaled nitric oxide in relation to asthma, allergic rhinitis, and atopic dermatitis in Chinese children.

Feng Xu1, Zhijun Zou, Shuxian Yan, Fei Li, Haidong Kan, Dan Norback, Gunilla Wieslander, Jinhua Xu, Zhuohui Zhao.   

Abstract

OBJECTIVE: Fractional exhaled nitric oxide (FeNO) is a non-invasive biomarker of airway inflammation. Our aim was to analyze the interrelationship and differentiate the predicting effects of asthma, allergic rhinitis (AR), and atopic dermatitis (AD) on the FeNO levels in children from mainland China.
METHODS: A case-control study with age- and gender matched 1:1 was designed based on a larger cross-sectional survey on asthma, AR, and AD in Shanghai. A self-administered questionnaire was used to collect information on children's health information. Children with positive reports on physician-diagnosed asthma and/or AR and/or AD were recruited as cases, and children with no report of any of the diseases were designated as controls. The FeNO measurement was performed online, using the NIOX MINO® instrument (Aerocrine AB, Solna, Sweden) at 50 ml/min.
RESULTS: A total of 130 subjects (65 cases and 65 controls, average age = 10 years) were recruited in this study. The average FeNO level was significantly higher in the cases (29.8 ± 1.9 ppb) than that in the controls (13.3 ± 1.7 ppb) (p < .001). Using multiple linear regression analysis controlling for confounding factors, including parental asthma/allergic diseases and home exposure, asthma (β = 0.330, p < .001) and AR (β = 0.157, p = .006) showed significant predicting effects for high FeNO levels, whereas AD was not related to the FeNO levels.
CONCLUSIONS: Both asthma and AR could independently increase the FeNO levels in Chinese schoolchildren. Other diseases besides asthma should be considered when applying FeNO as a screening tool for asthma in Chinese children.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22029828     DOI: 10.3109/02770903.2011.627487

Source DB:  PubMed          Journal:  J Asthma        ISSN: 0277-0903            Impact factor:   2.515


  6 in total

1.  Assessment of fractionated exhaled nitric oxide as a biomarker for the treatment of eosinophilic esophagitis.

Authors:  John Leung; Ann Nguyen-Traxler; Erika M Lee; Jason S Yip; Joel V Weinstock; Walter W Chan; Peter Ngo; Barbara J Weinstein; Peter A Bonis
Journal:  Allergy Asthma Proc       Date:  2012 Nov-Dec       Impact factor: 2.587

2.  Evaluation on exposures to particulate matter at a junior secondary school: a comprehensive study on health risks and effective inflammatory responses in Northwestern China.

Authors:  Hongmei Xu; Benjamin Guinot; Steven Sai Hang Ho; Yaqi Li; Junji Cao; Zhenxing Shen; Xinyi Niu; Zhuohui Zhao; Suixin Liu; Yali Lei; Qian Zhang; Jian Sun
Journal:  Environ Geochem Health       Date:  2017-10-10       Impact factor: 4.609

3.  Nasal nitric oxide in allergic rhinitis in children and its relationship to severity and treatment.

Authors:  Peng-Peng Wang; Gui-Xiang Wang; Wen-Tong Ge; Li-Xing Tang; Jie Zhang; Xin Ni
Journal:  Allergy Asthma Clin Immunol       Date:  2017-04-04       Impact factor: 3.406

4.  Gender and age affect the levels of exhaled nitric oxide in healthy children.

Authors:  Han Zhang; Linhua Shu; Xuxu Cai; Zhijia Wang; Xuyong Jiao; Fen Liu; Ping Hou; Li Wang; Lishen Shan; Ning Chen; Yunxiao Shang
Journal:  Exp Ther Med       Date:  2013-01-23       Impact factor: 2.447

5.  Determinants of Children's Exhaled Nitric Oxide: New Insights from Quantile Regression.

Authors:  Yue Zhang; Kiros Berhane; Sandrah P Eckel; Muhammad T Salam; William S Linn; Edward B Rappaport; Theresa M Bastain; Frank D Gilliland
Journal:  PLoS One       Date:  2015-07-27       Impact factor: 3.240

6.  The Effects of Indoor Pollutants Exposure on Allergy and Lung Inflammation: An Activation State of Neutrophils and Eosinophils in Sputum.

Authors:  Khairul Nizam Mohd Isa; Zailina Hashim; Juliana Jalaludin; Leslie Thian Lung Than; Jamal Hisham Hashim
Journal:  Int J Environ Res Public Health       Date:  2020-07-28       Impact factor: 3.390

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.